United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

daiichi sankyo uk ltd - amlodipine besilate; hydrochlorothiazide; olmesartan medoxomil - oral tablet - 10mg ; 12.5mg ; 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

daiichi sankyo uk ltd - olmesartan medoxomil; amlodipine besilate; hydrochlorothiazide - oral tablet - 40mg ; 5mg ; 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

daiichi sankyo uk ltd - olmesartan medoxomil; hydrochlorothiazide; amlodipine besilate - oral tablet - 40mg ; 25mg ; 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - valsartan; sacubitril - tablet - 51mg ; 49mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - sacubitril; valsartan - tablet - 24mg ; 26mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - sacubitril; valsartan - tablet - 97mg ; 103mg

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril - entresto is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entresto has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy.

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril - entresto is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entresto has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy